India  

Moderna COVID-19 vaccine

RNA COVID-19 vaccine

Moderna COVID-19 vaccine    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Moderna COVID-19 vaccine: RNA COVID-19 vaccine
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in people aged six months, twelve years, or eighteen years and older. It provides protection against COVID-19 which is caused by infection by the SARS-CoV-2 virus. It is designed to be administered as two or three 0.5 mL doses given by intramuscular injection at an interval of at least 28 days apart.

1
shares
ShareTweetSavePostSend
 

You Might Like


Moderna sues Pfizer/BioNTech over COVID vaccine

moderna sues pfizer/biontech over covid vaccine
Moderna is suing Pfizer and its German partner BioNTech for alleged patent infringement in the development of the first COVID-19 vaccine approved in the US.
Sky News - Published

Indian Covid vaccines better than Pfizer, Moderna: Adar Poonawalla

Serum Institute of India CEO Adar Poonawalla on Wednesday claimed that "Made in India" Covid vaccines have provided more protection against the coronavirus infection than mRNA vaccines like Pfizer and..
IndiaTimes - Published

Pfizer and Moderna jabs give best overall boost, UK study finds

pfizer and moderna jabs give best overall boost, uk study finds
The Pfizer and Moderna vaccines being used in the UK as boosters prompt the best overall response, according to a UK trial.
Sky News - Published

Omicron variant 'highly infectious' and COVID booster jabs may need 'double' dose, says Moderna CEO

omicron variant 'highly infectious' and covid booster jabs may need 'double' dose, says moderna ceo
The head of drugmaker Moderna said he believes the Omicron variant is "highly infectious" and it is "highly possible" the effectiveness of vaccines is decreasing - adding that boosters may need a..
Sky News - Published

New variant may force drug companies to tweak Covid vaccination plans

The emergence of the Omicron strain could lead drug companies scrambling to the drawing board to tweak their Covid-19 vaccine plans. US firm Novavax and Russia’s Gamaleya Institute said on Monday..
IndiaTimes - Published

With domestic manufacturing picking up pace, India unlikely to buy Pfizer, Moderna vaccines for now: Sources


IndiaTimes - Published

UK regulator approves Moderna COVID-19 vaccine for 12 to 17-year-olds

The UK health regulator has approved the Moderna coronavirus vaccine for 12 to 17-year-olds.
Sky News - Published